Keywords: PGE2 COX-2 Colon UPLC-MS/MS Pirc rat Endogenous biomarker FAP CRC a b s t r a c t An accurate and reliable UPLC-MS/MS method is reported for the quantification of endogenous Prostaglandin E2 (PGE 2 ) in rat colonic mucosa and polyps. This method adopted the "surrogate analyte plus authentic bio-matrix" approach, using two different stable isotopic labeled analogs -PGE 2 -d9 as the surrogate analyte and PGE 2 -d4 as the internal standard. A quantitative standard curve was constructed with the surrogate analyte in colonic mucosa homogenate, and the method was successfully validated with the authentic bio-matrix. Concentrations of endogenous PGE 2 in both normal and inflammatory tissue homogenates were back-calculated based on the regression equation. Because of no endogenous interference on the surrogate analyte determination, the specificity was particularly good. By using authentic bio-matrix for validation, the matrix effect and exaction recovery are identically same for the quantitative standard curve and actual samples -this notably increased the assay accuracy. The method is easy, fast, robust and reliable for colon PGE 2 determination. This "surrogate analyte" approach was applied to measure the Pirc (an Apc-mutant rat kindred that models human FAP) mucosa and polyps PGE 2 , one of the strong biomarkers of colorectal cancer. A similar concept could be applied to endogenous biomarkers in other tissues.
Introduction
Familial Adenomatous Polyposis (FAP) is a rare inherited disease [1] that results from an autosomal dominant genetic alteration in the adenomatous polyposis coli (APC) gene [2] . Patients with this disease characteristically develop hundreds to thousands of potentially pre-cancerous polyps (adenomas) in the duodenum, colon and rectum beginning in adolescence. Left untreated, patients have almost 100% lifetime risk of developing colorectal cancer (CRC) ultimately. Beyond early detection and surgical removal of the adenomatous precursor lesions, there is currently no safe and convenience therapeutic approach to FAP [3] . form for human FAP. For examples, polyp multiplicity significantly regressed when the Pirc rat was fed with celecoxib for 20-24 weeks [13] . This result is consistent with the human FAP clinical data [9] . Similar studies are also found for another COX-2 inhibitor, Sulindac, in Pirc rat and human [19, 21, 22] .
Although there is evidence [23] [24] [25] [26] that PGE 2 is a potent factor promoting intestinal polyps growth in APC min/+ mouse (an Apc-gene knock-out mouse model created 20 years prior to Pirc rat), the relationship between PGE 2 and Pirc colon polyps is yet not reported. Knowing such a relationship is very important and meaningful, because it would help to predict COX-2 inhibition of Pirc colon polyp growth.
To solve this problem, we established a new UPLC-MS/MS to accurately quantify colon tissue PGE 2 . The basic concept is to use a surrogate analyte PGE 2 -d9 replacing native PGE 2 , so that the validation can be conducted with authentic bio-matrices. We also show the MS response of PGE 2 and PGE 2 -d9 are essentially identical, hence the authentic bio-matrix based standard curve constructed with the surrogate analyte is adequate to quantify tissue PGE 2 concentration. This method was well validated with authentic tissue homogenate following FDA Guidance for Bioanalytical Method Validation (short for "FDA guidance" below). It was successfully applied for the quantification of colon tissue PGE 2 for both wild type and Pirc rat.
Experiment

Materials and reagents
PGE 2 (authentic analyte), PGE 2 -d4 (internal standard, I.S.) and PGE 2 -d9 (surrogate analyte) were purchased from Cayman Chemical Inc. (Ann Arbor, MI). Ethyl acetate, K 2 HPO 4 and KH 2 PO 4 were bought from VWR Corporate (Radnor, PA). Ammonium hydroxide and sucrose were supplied by Sigma-Aldrich (St. Louis, MO); and EDTA-Na 2 ·6H 2 O by J. T. Baker (Phillipsburg, NJ). Acetonitrile (HPLC grade) was obtained from OmniSolv (Billerica, MA). Distilled water, prepared from demineralized water, was used throughout the study.
Instruments and conditions
The UPLC-MS/MS consists of a Waters ACQUITY UPLC System (a quaternary solvent manager, a column manager, and a sample manager; Waters Corporation, MA. USA) and an API 5500 Q-Trap (AB Sciex, MA. USA) with an ESI interface. Data was processed with Analyst software (version 1.52).
Chromatographic separation was conducted on a UPLC BEH C18 column (2.1×100 mm, 1.7 m, Waters). A binary gradient consisting of 0.1% ammonium hydroxide solution (A) and acetonitrile (B) eluted in program: 0-6.5 min 13% B; 6.5-7.5 min from 13% to 80% B; 7.5-9.5 min 80% B; 9.5-10 min from 80% to 13% B; 10-15 min 13% B. The flow rate was 0.3 ml/min and the column temperature was Fig. 2A) , m/z 355.3->275.2 ( Fig. 2B ) and m/z 360.2->280.3 (Fig. 2C) . The optima DP and CE were −230 V and −22 V for all the compounds.
Animal treatments and sample collections
Pirc rats (raised at the Center for Epigenetics & Disease Prevention, Houston TX) were orally dosed with drug suspensions dissolved in 0.5% Methyl cellulose and 0.1% Tween-80, 40 mg/Kg, twice daily for successive 4 days (12-h dosing interval, and 8 doses in total). The normal control (wild type rat) and disease control (Pirc rat) were dosed with the same amount of blank vehicle solvent. Animals were sacrificed 6 h after receiving the last dose on Day 4; the colon polyps and mucosa were taken immediately and then kept in the −80 • freezer until analysis.
Homogenization buffer preparation
60 ml of 100 mM phosphate buffer solution (pH = 7), 51.344 g sucrose, 0.224 g EDTA dihydrate and 540 ml purified water were mixed and sonicated. The total volume was 600 ml, and the pH of the buffer was adjusted to 7.4.
Preparation of calibration curve and quality control
Stock solutions of 1 mg/ml PGE 2 , 50 g/ml PGE 2 -d4 (internal standard, I.S.) and 20 g/ml PGE 2 -d9 were prepared in acetonitrile. A series of PGE 2 and PGE 2 -d9 standard working solutions ranging from 3.908 to 1000 ng/ml were obtained by further dilution of the stock solution with acetonitrile. Matrix-matched calibration standards of PGE 2 -d9 at concentration levels of 0.098, 0.195, 0.391, 0.781, 1.563, 3.125, 6.25, 12.50 and 25.00 ng/ml were prepared by spiking an appropriate volume of the working solutions in nine aliquots of 2 ml tissue homogenate, respectively. The quality control (QC) samples were prepared at concentrations of 0.195, 1.563 and 20.00 ng/ml in the same bio-matrix. An internal standard working solution of 5 g/ml was prepared by diluting the stock solution of PGE 2 -d4 with acetonitrile. All the solutions were stored in −80 • C.
Sample preparation
The colonic mucosa and polyps were homogenized with 10 ml homogenization buffer after their weights were measured. 2 ml fractions of the homogenization samples and 20 l PGE 2 -d4 (5 g/ml internal standard stock solution, final concentration in 50 ng/ml) were mixed with 8 ml ethyl acetate for liquid-liquid extraction (LLE). The total 10 ml mixture was vortexed and centrifuged; then the upper supernatant was collected and transferred to another tube for nitrogen air dry. The collective dried residual was dissolved with 100 l reconstitution solvent (acetonitrile: 0.1% ammonium hydroxide = 2:8, v/v), then vortexed and centrifuged (15,000 rpm). 5 l of the supernatant was injected to UPLC-MS/MS for analysis.
Determination of relative response factor (RRF)
RRF was measured by UPLC-MS/MS using a series of neat solutions containing both authentic and surrogate analytes. The calibration curve was prepared the same as the matrix-matched calibration standards described on section 2.5, except using 2 ml of neat solution (acetonitrile: water = 2:8) to replace the tissue homogenate. The nominal concentrations of PGE 2 and PGE 2 -d9 are exactly the same in each point of this neat solution based calibration curve. The peak area ratios of authentic/surrogate analyte to internal standard were plotted against the nominal concentration, and standard curves were constructed using linear regression analysis with a 1/x 2 weighting factor (Eq. (1)). The actual PGE 2 and PGE 2 -d9 of each nominal concentration is back calculated using their individual fitting standard curves (Eq. (2)), and then the individual RRF is the ratio of actual PGE 2 to actual PGE 2 -d9 in the same nominal concentration (Eq. (3)). Finally, the average RRF is the calculated by averaging all the 9 individual RRFs.
Response of analyte
Where, a is the slope; b is the intercept;
At same nominal concentration (3)
Method validation
The selectivity was assessed by comparing the chromatograms of 8 different blank colonic mucosa and colon polyp homogenates from wild type and Pirc rats. No authentic analyte, surrogate analyte or internal standard was added into the blanks.
Calibration curves were constructed by analyzing spiked calibration surrogate analyte into the wild type mucosa homogenate. Samples were quantified using the peak area ratios of PGE 2 -d9 to PGE 2 -d4 (the I.S.). The peak area ratios were plotted against nominal concentration of PGE 2 -d9, and standard curves were constructed using linear regression analysis with a 1/x 2 weighting factor. The LLOQ was defined as the lowest concentration on the calibration curve; and its precision and accuracy should be within ± 20%.
To evaluate the precision and accuracy of the method, QC samples at three concentration levels (0.195, 1.563 and 20.00 ng/ml) were analyzed in five replicates on three different analysis batches. Assay precision is defined as the relative standard deviation (SD) from the mean (M), calculated by the equation RSD% = SD/M× 100%. Accuracy is defined as the relative deviation in the calculated value (E) of a standard from that of its true value (T) expressed as a percentage RE% (RE% = (E − T)/T × 100%). The accuracy, intra-and inter-day precisions are all required not to exceed 15%.
The matrix effect and recovery were determined by comparing responses from the analysis of five neat standards (set 1), five extracts of each of the different tissue homogenate samples spiked with the analyte and internal standard after extraction (set 2), and five extracts of each of the different tissue homogenate samples spiked with the compounds before extraction (set 3) at 0.195, 1.563 and 20.00 ng/ml of PGE 2 -d9. The matrix effect (%) was calculated by dividing peak areas of each compound in samples from set 2 by those in samples from set 1. Recovery (%) was calculated by dividing peak areas in samples from set 3 by those in samples from set 2.
The stabilities of PGE 2 -d9 in tissue homogenate were evaluated by analyzing replicates (n = 3) of samples at the concentrations of 0.195, 1.563 and 20.00 ng/ml. These samples were exposed to different conditions (time and temperature). Results were compared with those obtained from freshly prepared samples. The analytes are considered stable in the biological matrix when 85 − 115% of their initial concentrations are found. The bench-top (short-term) stability was determined after the exposure of the spiked samples at room temperature for 12 h, and the post-preparative stability in the auto-sampler (10 • C) was determined for 18 h. The long-term stability was assessed after storage of the standard spiked bio-samples at −80 • C for 2 week. The freeze-thaw stability was evaluated after three complete freeze-thaw cycles on consecutive days.
Tissue PGE 2 calculation
Tissue homogenate PGE 2 concentrations were calculated based on the regression equation of the calibration curve and the peak area ratio of endogenous analyte to internal standard. Because the RRF of PGE 2 to PGE 2 -d9 is almost equal 1 (0.99, see the result and discussion), the tissue PGE 2 concentration can be directly obtained from the PGE 2 -d9 matrix-match standard curve (Eq. (2) Fig. 2 ) [27] . However, many other endogenous PGs have the same cross-reaction ( Supplementary Fig. 3 ). Lacking specificity, the ELISA methods always overestimate the actual PGE 2 in biometrics [28] . The GC-MS can effectively separate PGs in sequence, so that the specificity and selectivity are well improved in comparison to ELISA. Incapable to gasify in GC-MS, PGE 2 needs chemical derivations in sample preparation prior to assay. This time and labor consuming step undermines the assay precision and accuracy.
Only 18 publications were found with the key words "PGE 2 and LC-MS" in Pubmed.gov from the year 2000 to the present day. Most measure PGE 2 in cell lines [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] and plasma/serum [38] [39] [40] [41] ; hence, it is difficult to be applied for tissue PGE 2 assays (since the endogenous interference is much more complex in tissues). M.Y. Golovko's team members keep improving the LC-MS assay method for brain tissue PGE 2 ; and they have published 3 papers [42] [43] [44] . Their studies makes good contributions to sample purifications and chromatographic separations. A UPLC-MS/MS method was reported for determination of tissue PGE 2 in their latest paper [42] ; but the matrix used for standard curve preparation as well as method validation was not clearly specified − this has great influence on the assay accuracy. If the validation matrix was buffer or neat solution (like the experiment in which the actual bio-matrix was replaced by artificial cerebrospinal fluid for PGE 2 assay [45] ); the tissue PGE 2 will be highly underestimated. The PGE 2 signal response is much higher in neat solution than in tissue homogenate (as we found it in our experiment); because the neat solution does not suffer from ion-suppression (matrix effect) or extraction loss (recovery) [46] . On the other hand, if the validation matrix was the authentic tissue homogenate, the assay unavoidably suffers the background interference from endogenous PGE 2 . According to the FDA guidance, the limit of quantitation (LOQ) of analyte should be necessary to generate a characteristic signal at least 10-fold higher than the background noise; but inflamed tis- sue cannot generate PGE 2 10 fold higher than background level. In summary, whatever matrices they used for validation, there is always a concern for accuracy.
Quantification of endogenous compounds
The FDA guidance strongly recommends using the same matrices as the test sample for standard curve preparation, to ensure equal signal responses for equal concentrations of analyte in both standard reference and test sample. For endogenous substances, however, there is no real analyte-free bio-matrices available. Four approaches [46, 47] are commonly adopted to assay endogenous compounds by LC-MS/MS lacking blank matrices, including background subtraction, standard addition, surrogate matrix, and the surrogate analyte approaches.
Both "background subtraction" and "standard addition" approaches require that the analyte signal in all the test samples should be much higher than the endogenous background (at least 20 fold); otherwise the error will lead to inaccurate quantification. Since the inflammation tissue PGE 2 only is several folds higher than the normal tissue in this study, these two methods are obviously not suitable. The surrogate matrix method uses neat solutions, artificial matrices or stripped matrices to lower down even diminish the endogenous background. However, it usually does not account for actual extraction recovery and matrix effect that are highly different between authentic bio-matrices and artificial matrices. Finally, the remaining choice is the surrogate analyte approach. The surrogate analyte method was firstly proposed by W. Li and L. Cohen from Pfizer Company in 2003 [48] . The basic concept is to build the calibration curve, using the signal response from a stable labeled surrogate analyte, and calculate the sample concentrations of endogenous analyte based on the regression equation from the surrogate standard. This concept has been successfully applied for determinations of other endogenous biomarkers [47, [49] [50] [51] [52] [53] [54] .
In our study, the calibration standard was prepared with PGE 2 -d9 combining with colonic mucosa homogenate (the authentic bio-matrix), and no background interference from biological matrices was found for PGE 2 -d9 ( Fig. 3F and M) . Because the intrinsic physical and chemical properties of PGE 2 and PGE 2 -d9 are almost identical, their chromatographic retentions, MS ionization efficiencies, extraction recoveries and matrix effects from tissue homogenate are the same. The individual RRF ranges from 0.95 to 1.04 in this assay, and the average RRF is 0.99 (Table 1) . It establishes Fig. 3 . Typical chromatograms for method specificity. The retention times of PGE2 (A), PGE2-d4 (B) and PGE2-d9 (C) reference standards were almost identical at about 4.5 min. A low level of endogenous PGE2 was detected in wild type colonic mucosa (D), but no background interference was found for PGE2-d4 (E) and PGE2-d9 (F). The LLOQ (as well as quantification standard curve) was constructed with wild type colonic mucosa by adding the surrogate analyst PGE2-d9 (J), and then measured by adding the internal standard PGE2-d4 (I). Similar endogenous background was also found for PGE2 (H) in the LLOQ. This method can effectively separate the PGE2 and PGD2 (confirmed with PGD2 reference standard) in the actual colon polyp samples (K).
that the sample PGE 2 can be directly calculated from the PGE 2 -d9 standard curve.
Important note: If RRF is not equal to 1, the concentration calculated by the surrogate standard curve should be calibrated by this factor. (Some factors may result in response differences [47, 48] including, ionization difference, gas-phase deuterium exchange, inaccurate purity characterization, kinetic isotope effect and compression of isotope distribution for stable isotope labeled analyte comparing to the native analyte.) Some issues [46] to be aware of when the "surrogate analyte" approach is used include contamination of labeled standards with trace levels of unlabeled compounds, unequal MS responses, commercial availability, stability and degradation to the unlabeled standards over time. However, there are some rules of choosing the stable labeled surrogate which can avoid the unnecessary troubles: 1) The mass difference between any two analytes should be more than 3 Da; 2) the label position should not be the metabolism spot or the active hydrogen (e.g. OH or COOH); 3) All the solutions and samples are suggested to be stored in the −80 • C freezer.
LC method development
A good LC separation guarantees the reliability and robustness of this assay, because the MS analyzer cannot separate PGE 2 from many other endogenous prostaglandin isomers that have the same MRM transitions as PGE 2 . The UPLC C18 BEH column (2.1 mm * Fig. 4 . No contamination or cross-talk among PGE2, PGE2-d4 and PGE2-d9. (Limit of detection is about 0.5 pg/ml). Three different neat standard solutions (concentration in 3-5 ng/ml, about 10,000 folds above LOD) were injected separately, and the MS analyzer detected three different MRM transitions simultaneously. The PGE2 solution only shows one peak in its own MRM transition at 4.6 min (A), and no peak at the same retention time in other MRM transitions that belong to PGE2-d4 (B) and PGE2-d9 (C). Similarly, PGE2-d4 (E) and PGE2-d9 (I) only show one peak in their individual MRM transition. 100 mm, 1.7 m) was finally used, because it had the best separation performance among all the tested columns. Pure water, water with ammonium acetate and formic acid were initially tested, but they were incapable to achieve a good baseline separation for PGE 2 and PGD 2 before 20 min (which is too long for the assays).
In contrast, 0.1% NH 4 OH solution provided an ideal separation, with good flexibility and convenience. The separation performance of 0.1% NH 4 OH for PGE 2 and PGD 2 was at least 10 fold higher than that of other mobile phases mentioned above. In this reported method, PGE 2 and PGD 2 were fully separated before 6 min (in a flow rate 0.3 ml/min, Fig. 3K ). The mechanism is probably to increase the polarity of PGE 2 , making its retention behavior much different from other endogenous interferences.
Another advantage of 0.1% NH 4 OH solution is to enhance the sensitivity. In ESI negative ionization, the analyte loses one proton in order to carry one charge. Containing one carboxyl acid moiety, PGE 2 can easily deprotonate with 0.1% NH 4 OH mobile phase thereby increasing its MS response on negative mode. We found that the PGE 2 sensitivity increases 10 fold when the aqueous phase was changed from 0.1% HCOOH to 0.1% NH 4 OH. (Note: 0.1% HCOOH strongly inhibited the ESI (−) signal response.)
One important information is worthy of mention for the NH 4 OH mobile phase, since it is not a common mobile phase. The safe pH range for most conventional HPLC columns is from 2 to 8, and any pH beyond this range may ruin the silicon bedding of the column. The waters BEH material can withstand a pH range from 1 to 12, therefore it is safe for the 0.1% NH 4 OH (pH = 10). Fig. 3 shows the specificity of this method. The retention times of PGE 2 , PGE 2 -d4 and PGE 2 -d9 were about 4.5-4.6 min (Fig. 3A , B and C; Note: the number of deuterium slightly changes the retention time [48] ). A low level of endogenous PGE 2 was detected in wild type rat colonic mucosa (Fig. 3D) , but no background interference was found for PGE 2 -d4 (Fig. 3E) or PGE 2 -d9 (Fig. 3F) . The LLOQ was constructed with wild type colonic mucosa by adding the surrogate analyte PGE 2 -d9 (Fig. 3J) , and then measured by adding the internal standard PGE 2 -d4 (Fig. 3I) . Similar endogenous background was also found for PGE 2 (Fig. 3H) in the LLOQ. This method efficiently separated the PGE 2 and PGD 2 (confirmed with PGD 2 reference standard) in the actual colon polyp samples (Fig. 3K) .
Method validation
The purity of the stable labeled compounds (surrogate analyte and internal standard) is critically important. The detection limit, linearity and accuracy will be undermined if the isotope labeled substances do not have sufficient purity (> 98%). Therefore, 3-5 ng/ml neat standard solutions were injected. No unlabeled impurity or cross-talk influence was found (Fig. 4) . The selected assay range for PGE 2 -d9 fulfilled the criteria for the LLOQ concentration and the calibration curve. The typical regression equation from calibration curves was: f = 1.09 * C − 0.00281, r = 0.9978
Where f represents the peak area ratio of surrogate analyte to the I.S.; and C represents the concentration of PGE 2 -d9. Because the RRF is 0.99 (almost equal to 1, Table 1 ), the authentic analyte PGE 2 can be directly calculated by this PGE 2 -d9 bio-matrix based standard curve. The LLOQ was 97 pg/ml for PGE 2 with good accuracy and precision (90% and 3%, n = 5). Table 2 summarizes the intra-and inter-assay precision and accuracy of the method. Both intra-and inter-assay precisions tested with PGE 2 -d9 were less than 10%, and the precision of three batches of endogenous PGE 2 was 6%. The above results demonstrated that the values were within the acceptable range and the method was deemed to be accurate and precise.
The absolute matrix effects for PGE 2 -d9 at concentrations of 0.195, 1.560 and 20.00 ng/ml were 96, 94 and 99%, respectively; for the I.S. was 106%. Mean extraction recoveries of PGE 2 -d9 were 99%, 95% and 99% and that of the internal standard was 97%.
Sample stability evaluations were designed to cover the anticipated conditions of processing of the bio-samples (Table 3) . PGE 2 -d9 was stable during sample storage (at room temperature for 12 h, at −80 • C for 2 week), processing (three freeze-thaw cycles) and post-treatment (in the reconstituted extract at 10 • C for 18 h). All RE values between post-storage and initial QC samples were within ± 15%. Meanwhile, the authentic analyte (background PGE 2 ) was also proven to be stable (Table 3) . numerous microadenomas. In untreated Pirc, the polyp PGE 2 level was two fold higher than adjacent mucosa (p = 0.016), thus confirming the current belief that PGE 2 promotes colorectal cancer. In this study, short-term celecoxib treatment reduced mucosa PGE 2 by 57% (p = 0.014) and polyp PGE 2 by 29% (p = 0.12). The result shows celecoxib decreases colon PGE 2 and is capable of suppressing polyp growth. The variable inhibition observed between PGE 2 within polyps and colonic mucosa might be contributed by the discrepancy in surface area and physiological barrier. Celecoxib can easily hit the COX-2 target in the barrier-free mucosa that has large surface area., Notably, celecoxib reduced the Pirc mucosa PGE 2 back to normal (compared to wild type, p = 0.788) with a short treatment. We expect that mucosa PGE 2 should be maintained in this reduced level long-term drug treatment (24 weeks). The PGE 2 reduction mechanism could explain why a 24-week celecoxib treatment (similar dose as we used in this study) remarkably decreased the Pirc polyp burden [13] . The main discrepancy in this study is that the polyp PGE 2 did not significantly decline as expected initially. Perhaps the treatment duration was too short (only 4 days). A longer dosing (2-3 months) corroborate this expectation.
Application
In conclusion, Pirc rat is a good animal model for human FAP study; and the mucosa PGE 2 inhibition is a good indicator for antipolyp efficacy in short-term study when the Pirc is treated with COX-2 inhibitors.
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